United against Parkinson’s Disease

Parkinson’s Disease

As Emile Nuwaysir, Chairman of the Board and former CEO of BlueRock Therapeutics reflects on the company’s progress and future, he says, “We have an opportunity here to change the paradigm.”

We know that innovation is key to the future of healthcare and to bringing new and needed treatments to patients. We also understand that traditional funding methods may not always be suitable for early start-ups or established biotech companies with a short runway.


Therefore, two top priorities for us are challenging the paradigm in how degenerative diseases are addressed and forging mutually beneficial partnerships that empower our partners to thrive.


To achieve these goals, and recognizing that every partner is unique, we are committed to customizing our partnership models to meet the specific needs of our partners.


One example is illustrated by BlueRock, which was co-founded by our Leaps by Bayer impact investment unit, together with a venture capital company and the world’s leading scientists in induced pluripotent stem cells (iPSC) technology. Soon afterwards, we established our arm’s length model and fully acquired BlueRock. With the arms-length model, our wholly-owned, independently operated subsidiaries are able to maintain their entrepreneurial culture, attract exceptional talent, embark in partnerships and collaborations, and expand their locations.


We recognize that biotechs need a comprehensive suite of resources to succeed. This is why our arm’s length companies can leverage our expertise across multiple fields including (but not limited to) manufacturing, pharmacovigilance, and commercialization. Our experts are available to provide guidance and support, as well as networking and mentorship. In addition, we offer state-of-the-art facilities and equipment so our partners can grow and flourish.


Most importantly, we understand that the success of a biotech company depends on its people. Their creativity, entrepreneurial spirit, and complementary talents are essential to driving innovation and advancing the field. Our goal in partnering with biotechs is to allow them to focus on what they do best: science.


“Let's Put an End to Parkinson's. Together.”1


By working together with BlueRock, we are creating exciting new ideas, transforming healthcare, and improving the lives of patients worldwide.

United against Parkinson’s Disease